Selected article for: "administration route and intravenous administration"

Author: Randall Toy; Pallab Pradhan; Vijayeetha Ramesh; Nelson C. Di Paolo; Blake Lash; Jiaying Liu; Emmeline L. Blanchard; Philip J. Santangelo; Dmitry M. Shayakhmetov; Krishnendu Roy
Title: Modification of primary amines to higher order amines reduces in vivo hematological and immunotoxicity of cationic nanocarriers through TLR4 and complement pathways
  • Document date: 2019_5_24
  • ID: cbit5xci_30
    Snippet: We evaluated the systemic toxicity of cationic nanoparticles after intravenous (IV) delivery, which is an administration route associated with high levels of toxicity. [29] Our initial in vivo experiments probed serum levels of the pro-inflammatory cytokines IL-6 ( Fig. 2A No detectable amounts of TNF-a and IL-1b were measured after in vivo administration of either bPEI formulation. Unmodified chitosan nanoparticles induced in vivo production of .....
    Document: We evaluated the systemic toxicity of cationic nanoparticles after intravenous (IV) delivery, which is an administration route associated with high levels of toxicity. [29] Our initial in vivo experiments probed serum levels of the pro-inflammatory cytokines IL-6 ( Fig. 2A No detectable amounts of TNF-a and IL-1b were measured after in vivo administration of either bPEI formulation. Unmodified chitosan nanoparticles induced in vivo production of IL-6, TNFa, and IL-1b. Behavioral evaluation of mice 30 minutes after IV injection supported our serum cytokine and ALT data. When treated with unmodified chitosan or bPEI nanoparticles, the mice suffered from discomfort and lethargy in comparison to naïve, untreated mice. In mice treated with IAA-modified chitosan or bPEI nanoparticles, the symptoms of lethargy were reduced.

    Search related documents:
    Co phrase search for related documents
    • administration route and IV injection: 1
    • administration route and pro inflammatory cytokine: 1
    • administration route and serum cytokine: 1
    • administration route and systemic toxicity: 1
    • administration route and vivo production: 1